<DOC>
	<DOCNO>NCT01244503</DOCNO>
	<brief_summary>The purpose study demonstrate ¹³C-Octanoate Breath Test ( OBT ) use aid , conjunction clinical information medical history , evaluate disease severity detect NASH high probability .</brief_summary>
	<brief_title>Prediction Severity Liver Disease 13C Octanoate Breath Test ( OBT )</brief_title>
	<detailed_description>The OBT chosen ass , along parameter , liver health subject suspect NAFLD ( non alcoholic fatty liver disease ) . Octanoate absorb promptly intestinal lumen transport rapidly liver portal venous system , enters hepatic mitochondrion independently carnitine transport system undergoes hepatic mitochondrial beta-oxidation produce acetyl coenzyme A ( CoA ) . Finally , acetyl CoA enters Krebs cycle oxidize carbon dioxide ( CO2 ) . This non invasive test perform routinely every visit ass disease severity . The subject connect breath analyzer via nasal cannula approximately 1 hour , measure baseline breath change delta baseline due metabolization Octanoate .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult men woman ( &gt; 18 year age ) • Liver biopsy ( least 1.7 cm 4 portal tract ) perform within 6 month breath test plan within next 6 week , provide treatment liver disease give biopsy OBT Any elevation liver enzymes upper limit normal ( follow : AST , ALT , GGT , Alkaline phosphatase ) At least one feature metabolic syndrome waist circumference &gt; 100 cm men , 88 cm woman triglyceride &gt; 150 mg/dl fast blood sugar &gt; 110 mg/dl HDL cholesterol &lt; 40 mg/dl blood pressure &gt; 130/85 mm Hg No known coexistent liver disease , exclude appropriate serologic test Positive study follow : hepatitis C ( PCR ) hepatitis B ( surface antigen DNA ) iron saturation &gt; 60 % + gene test hereditary hemochromatosis antinuclear antibody titer &gt; 1 : 160 along hypergammaglobulinemia ALT level &gt; 250 U/L Patient Alpha1antitrypsin level lower limit normal ( &lt; 150 mg/dl ) Patient alcohol consumption &gt; 20 gm/day woman &gt; 30 gm/day men Patient pregnant Patient take know hepatotoxic drug e.g . ( e.g.acebutolol , indomethacin , phenylbutazone , allopurinol , isoniazid , phenytoin , atenolol , ketoconazole , piroxicam , carbamazepine , labetalol , probenecid , cimetidine , maprotiline , pyrazinamide , dantrolene , metoprolol , quinidine , diclofenac , mianserin ) • Patients 10 % reduction body weight since biopsy Patient know severe congestive heart failure ( LVEF echocardiogram &lt; 20 % ) Patient know severe pulmonary hypertension ( By echocardiogram , PAS &gt; 45 mmHg ) Patient uncontrolled diabetes mellitus ( HA1c &gt; 10 ) Patient previous surgical bypass surgery Patient extensive short bowel syndrome ( &gt; 100 cm ) Patient currently receive total parenteral nutrition Patient recipient organ transplant Patients receive antiviral treatment liver therapy time biopsy breath test . Women pregnant Patients acute current exacerbation chronic obstructive pulmonary disease bronchial asthma . Patient take drug interfere octanoate metabolism also cause NAFLD independent metabolic syndrome , include : corticosteroid , amiodarone , tetracycline , valproic acid , methotrexate , stavudine , zidovudine . Patients unable refuse sign inform consent Patients base opinion investigator enrol study Patients participate clinical trial evaluate experimental treatment procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>